Deutsche Bank AG Sells 237,820 Shares of Evolus, Inc. (NASDAQ:EOLS)

Deutsche Bank AG cut its stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 43.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 307,769 shares of the company's stock after selling 237,820 shares during the period. Deutsche Bank AG owned 0.49% of Evolus worth $3,398,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of EOLS. Tri Locum Partners LP acquired a new stake in Evolus during the fourth quarter worth approximately $8,198,000. Gilder Gagnon Howe & Co. LLC lifted its position in Evolus by 287.2% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company's stock worth $7,753,000 after acquiring an additional 520,859 shares during the last quarter. Caligan Partners LP lifted its position in Evolus by 22.7% during the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock worth $29,724,000 after acquiring an additional 498,900 shares during the last quarter. Allostery Investments LP acquired a new stake in Evolus during the fourth quarter worth approximately $4,760,000. Finally, Altium Capital Management LLC lifted its position in Evolus by 93.0% during the fourth quarter. Altium Capital Management LLC now owns 685,000 shares of the company's stock worth $7,562,000 after acquiring an additional 330,000 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Evolus news, insider Rui Avelar sold 27,904 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the transaction, the insider now directly owns 362,467 shares in the company, valued at $4,806,312.42. The trade was a 7.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $60,147.36. Following the transaction, the chief marketing officer now owns 95,671 shares of the company's stock, valued at approximately $1,268,597.46. This represents a 4.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 86,241 shares of company stock worth $1,048,666. Corporate insiders own 5.90% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on EOLS shares. HC Wainwright restated a "buy" rating and set a $27.00 price objective on shares of Evolus in a research report on Thursday, April 10th. Barclays raised their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Evolus in a research report on Thursday, May 8th. Finally, BTIG Research assumed coverage on shares of Evolus in a research report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $23.75.

Evolus Price Performance

Shares of NASDAQ EOLS traded up $0.12 during midday trading on Monday, reaching $9.68. The company's stock had a trading volume of 462,704 shares, compared to its average volume of 694,791. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a fifty-two week low of $8.67 and a fifty-two week high of $17.82. The business's 50 day moving average price is $10.89 and its two-hundred day moving average price is $12.05. The company has a market cap of $624.13 million, a P/E ratio of -10.64 and a beta of 1.11.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.